CMX-2043|cas:910627-26-8|西域试剂

CMX-2043,96.16%

产品编号：Bellancom-119152| CAS NO：910627-26-8| 分子式：C₁₆H₂₆N₂O₆S₂| 分子量：406.52

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-119152		￥3900.00	杭州北京（现货）
Bellancom-119152		￥5850.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

CMX-2043

产品介绍

CMX-2043 是 α-Lipoic Acid (HY-N0492) 新型类似物。CMX-2043 具有抗氧化作用，能够激活胰岛素受体激酶，可溶性酪氨酸激酶，和促 Akt 磷酸化。CMX-2043 在大鼠缺血再灌注损伤 (IRI) 模型中表现出保护作用。

生物活性

CMX-2043 is a novel analogue of α-Lipoic Acid (HY-N0492). CMX-2043 is effective in antioxidant effect, activation of insulin receptor kinase, soluble tyrosine kinase, and Akt phosphorylation. CMX-2043 shows protection against ischemia-reperfusion injury (IRI) in rat model.

体外研究

CMX-2043 (15-250 mM; 10 min) has great peroxyl radical absorbance capacity.
CMX-2043 (1.5 μM) weakly inhibits spleen tyrosine kinase (Syk) and tunica interna endothelial cell kinase (Tie2).
CMX-2043 (50 μM; 45 min) activates Akt phosporylation via PI3K pathway in A549 cells.
CMX-2043 (2.5 mM; 30 min) diminishes the rise in cytosolic calcium in a concentration-dependent manner in CHO-M1-WT3 cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Immunofluorescence

Cell Line:	H9c2 (rat cardiac myocyte) cells
Concentration:	50 μM
Incubation Time:	3 hours
Result:	Showed brighter luorescence intensity in cells compared with control, indicating a stronger Akt phosphorylation effect.

体内研究
(In Vivo)

CMX-2043 (50-200 mg/kg, 5 mL; p.o.; single dose) reduces myocardial ischemia-reperfusion injury (IRI) as measured by the myocardial infarct to area at risk (MI-AR) ratio and the incidence of arrhythmia.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ischemia-reperfusion injury (IRI) model in Sprague Dawley rats
Dosage:	50, 100, and 200 mg/kg; 5 mL of normal saline solution containing 2% vanilla extract as flavoring
Administration:	Oral gavage; single dose; induced IRI 30-60 min after treatment
Result:	Induced arrhythmia and mortality of rats with reducing the ratio of myocardial infarct to area at risk.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ischemia-reperfusion injury (IRI) model in Sprague Dawley rats
Dosage:	50, 100, and 200 mg/kg; 5 mL of normal saline solution containing 2% vanilla extract as flavoring
Administration:	Oral gavage; single dose; induced IRI 30-60 min after treatment
Result:	Induced arrhythmia and mortality of rats with reducing the ratio of myocardial infarct to area at risk.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Ischemia-reperfusion injury (IRI) model in Sprague Dawley rats
Dosage:	50, 100, and 200 mg/kg; 5 mL of normal saline solution containing 2% vanilla extract as flavoring
Administration:	Oral gavage; single dose; induced IRI 30-60 min after treatment
Result:	Induced arrhythmia and mortality of rats with reducing the ratio of myocardial infarct to area at risk.

性状

Solid

溶解性数据

In Vitro:

DMSO : 20.83 mg/mL (51.24 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.4599 mL	12.2995 mL	24.5990 mL
5 mM	0.4920 mL	2.4599 mL	4.9198 mL
10 mM	0.2460 mL	1.2300 mL	2.4599 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (5.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.12 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: 2.08 mg/mL (5.12 mM); Suspended solution; Need ultrasonic

此方案可获得 2.08 mg/mL (5.12 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (5.12 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (5.12 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。